Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanofi/GSK B.1.351 vs Pfizer 2nd Booster in Adults ≥60
NCT05405283Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of monovalent [B.1.351] CoV2 preS dTM-AS03 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Immunogenicity of a second booster at 15 days. Status: unknown.
02
Drugs
monovalent [B.1.351] CoV2 preS dTM-AS03
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05405283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405283.